Uncategorized
Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical biopharmaceutical company developing drugs for the eye, announces last patient enrolled in Phase 2 trial for macular edema associated with retinal vein occlusion.
